Science and Research

A randomized, double-blind, placebo-controlled, parallelgroup, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis

A randomized, double-blind, placebo-controlled, parallelgroup,
Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis

Study details
Study-ID: 2023-508663-70
DZL Disease Area: CFBE
Study Type: Interventional
DZL Role: DZL recruiting center
Funding: Externally - industry
DZL Participating Sites: CPC-M
Start Date: 26.09.2024
Completion Date: 31.12.2025
Status: Recruiting


chevron-down